阿西替尼和口服节拍依托泊苷治疗儿童和 AYA 难治性/复发性髓母细胞瘤和室管膜瘤 (MEPENDAX)
MEPENDAX:阿西替尼 (Inlyta®) 和口服节拍依托泊苷治疗儿童和 AYA 难治性/复发性髓母细胞瘤和室管膜瘤的 I/II 期研究
It is an open multicentric phase I/II trial with axitinib (Inlyta®) and metronomic delivery of etoposide for children, adolescent and young adults (AYA) with refractory/ relapsing solid tumors. It is a two-stage trial:
First stage: To determine the Maximum Tolerated Dose (MTD) of the combination of axitinib and oral metronomic etoposide for patient with medulloblastoma or ependymoma Second stage: Extension cohort evaluating the preliminary efficacy at the recommended dose for the phase II (RDP2) of the combination. The 2nd stage will start after a meeting of independent data monitoring committee (IDMC). Two cohorts of 9 patients with ependymoma and medulloblastoma Patients treated at first stage won't be included in the second stage.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Nicolas ANDRE
- 电话号码:0491386792
- 邮箱:nicolas.andre@ap-hm.fr
研究联系人备份
- 姓名:Franceline CARTIER
- 邮箱:franceline.cartier@ap-hm.fr ; promotion.interne@ap-hm.fr
学习地点
-
-
-
Angers、法国
- 招聘中
- Centre Hospitalier Universitaire D'Angers
-
接触:
- BRISSET
- 电话号码:0241356524
- 邮箱:claire.brisset@chu-angers.fr
-
Bordeaux、法国
- 招聘中
- Centre Hospitalier Universitaire De Bordeaux
-
接触:
- ICHER
- 电话号码:0557820448
- 邮箱:celine.icher@chu-bordeaux.fr
-
Lyon、法国
- 招聘中
- IHOPe Institut d'Hématologie et d'Oncologie Pédiatrique
-
接触:
- LEBLOND
- 电话号码:0469166550
- 邮箱:pierre.leblond@ihope.fr
-
Marseille、法国
- 招聘中
- Assistance Publique - Hôpitaux de Marseille
-
接触:
- Nicolas Andre
- 电话号码:+330491386821
- 邮箱:nicolas.andre@ap-hm.fr
-
Nancy、法国
- 招聘中
- CHRU De Nancy
-
接触:
- Marie-Sophie MERLIN
- 电话号码:+33 0383154734
- 邮箱:m.merlin@chru-nancy.fr
-
Paris、法国
- 招聘中
- Institut Curie
-
接触:
- LERUSTE
- 电话号码:0144324015
- 邮箱:amaury.lereuste@curie.fr
-
Strasbourg、法国
- 招聘中
- Les Hopitaux Universitaires De Strasbourg
-
接触:
- Natacha ENTZ-WERLE
- 电话号码:+33 0388128097
- 邮箱:natacha.entz-werle@chru-strasbourg.fr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically proven diagnosis of ependymoma or medulloblastoma
- Methyloma classification performed or available material for methyloma analysis
- Confirmed progressive or refractory disease despite standard therapy, or for which no effective standard therapy exists
- Male and female subjects with > 4 to ≤ 25 years of age at inclusion
- Weight > 20 kg
- Evaluable target lesion(s) according to RAPNO
- Performance status: Karnofsky performance status (for patients >12 years of age) or Lansky Play score (for patients ≤12 years of age) ≥ 70%. Patients who are unable to walk because of paralysis or stable neurological disability, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
- Life expectancy ≥ 3 months
- No known allergy to any of the compounds in the experimental treatment
- Able to take oral treatments
- Adequate organ function:
Hematologic criteria
- Peripheral absolute neutrophil count (ANC) ≥ 1000/mm3 (unsupported)
- Platelet count ≥ 100,000/mm3 (unsupported)
- Hemoglobin ≥ 8.0 g/dL (transfusion is allowed) Cardiac function
- Shortening fraction (SF) >29% and left ventricular ejection fraction (LVEF) ≥50% at baseline, as determined by echocardiography (mandatory only for patients who have received cardiotoxic therapy).
Renal and hepatic function
-
Serum creatinine < 1.5 x upper limit of normal (ULN) for age
-
Total bilirubin < 1.5 x ULN
-
Alanine aminotransferase (ALT)/ Aspartate aminotransferase (AST)/ < 2.5 x ULN
- Able to comply with scheduled follow-up and with management of toxicity.
- Females of child bearing potential must have a negative serum pregnancy test within 7 days prior to initiation of treatment.
- Sexually active patients must agree to use adequate and appropriate contraception (in accordance with Clinical Trials Facilitation and Coordination Group (CTFG) recommendations) while on study drug and for 6 months after stopping the study drug.
- Patient able to comfortably swallow capsules.
- Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted according to local, regional or national guidelines.
- Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.
Non-inclusion Criteria
- Chemotherapy within 21 days of day 1 from the start of study treatment. This period can be shortened in the case of treatment with vincristine (2 weeks) and extended to 6 weeks in the case of treatment with nitrosureas. The period is set to 5 half-lives in the case of targeted therapies or metronomic chemotherapy. The period is set to 2 weeks after bevacizumab administration. Evidence of > Grade 1 recent CNS hemorrhage on the baseline MRI or scan.
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
- Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).
- Known active viral hepatitis or known human immunodeficiency virus (HIV) infection or any other uncontrolled infection.
- Presence of any NCI-CTCAE v5 grade ≥ 2 treatment-related extra-hematological toxicity with the exception of alopecia, ototoxicity or peripheral neuropathy.
- Known congenital immunodeficiency.
- Radiotherapy within the 2 months preceding D1 of the start of study treatment. Palliative RT on a non-target lesion is allowed up to 1 weeks before beginning of treatment.
- Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48 hour interval must be maintained before the first dose of the investigational drug is administered.
- Bleeding disorder.
- Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).
- Known hypersensitivity to any study drug or component of the formulation.
- Absence of effective contraception in patients of childbearing age (see appendix 3)
- Pregnant or nursing (lactating) females.
- Patients with galactose intolerance, lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary diseases).
- Severe infections requiring parenteral antibiotic therapy.
- Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Patients receiving axitinib in combination with etoposide
|
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Dose-limiting toxicity (DLT)
大体时间:During the first 28 days (cycle 1)
|
During first stage |
During the first 28 days (cycle 1)
|
|
Progression-free survival (PFS)
大体时间:3 years (from start of treatment to last follow-up visit)
|
During second stage, progression-free survival (PFS) computed as the time interval from the beginning of treatment to the date of centrally-assessed with RAPNO criteria. A central review of all imaging is planned at the end of phase 1 and at the end of phase expansion to evaluate tumor response and progressions. PFS-duration of patients alive free of progression at last follow-up will be censored at the date of last visit. |
3 years (from start of treatment to last follow-up visit)
|
合作者和调查者
调查人员
- 首席研究员:Nicolas ANDRE、Assistance Publique - Hôpitaux de Marseille
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.